Jublia (efinaconazole 10% solution) treats toenail fungus by blocking the production of ergosterol, a molecule that fungal cells need to build and maintain their outer membranes. Without ergosterol, the fungal cell membrane breaks down, and the organism dies. What makes Jublia unusual among topical treatments is not just this killing mechanism but also its physical ability to pass through the hard nail plate and reach the fungus living underneath, a feat that older topical antifungals struggle with.
Why Toenail Fungus Is Difficult to Treat
Toenail fungus, known clinically as onychomycosis, is not a surface problem. The fungi responsible, usually dermatophytes like Trichophyton rubrum, invade through the nail and set up shop in the nail bed and the spaces between keratin layers. Laboratory studies using nail fragments have shown that dermatophyte spores can adhere and germinate within hours of contact, forming visible colonies within a day and covering most of a nail fragment in fungal growth within about three days. The invasion happens through the spaces between cells in the nail, driven by a combination of mechanical force and enzyme activity.
1British Journal of Dermatology. Early events in the invasion of the human nail plate by Trichophyton mentagrophytesThis matters for treatment because the nail itself is one of the hardest biological barriers for drugs to cross. The nail plate is made of tightly packed keratin protein, with filaments running across the direction of nail growth and linked together by multiple types of chemical bonds. The thicker the nail, the harder it is for a drug to get through.
2New Horizons in Translational Medicine. Drug delivery through nails: Present and future This dense keratin barrier is a major reason topical treatments for toenail fungus have historically underperformed compared to oral medications. Low diffusion through the nail and reduced drug availability at the site of infection have been persistent obstacles.3PubMed Central. Recent Patents on Permeation Enhancers for Drug Delivery Through Nails
How Jublia Disrupts the Fungal Cell
Efinaconazole, the active ingredient in Jublia, belongs to a class of antifungals called triazoles. Its primary target is an enzyme called lanosterol 14α-demethylase, which fungi need to convert lanosterol into ergosterol. Ergosterol is essentially the fungal equivalent of cholesterol: a structural lipid that keeps the cell membrane stable and functional. When Jublia blocks this enzyme, the fungus can no longer produce ergosterol and instead accumulates abnormal sterol precursors. These abnormal sterols weaken the membrane, causing the cell to deteriorate and eventually die.4PubMed Central. Mechanism of action of efinaconazole, a novel triazole antifungal agent
This mechanism is not unique to Jublia; several other antifungals target ergosterol production. What sets efinaconazole apart is the breadth of fungi it covers and the potency with which it works. It has strong activity against dermatophytes, the most common cause of toenail infections, but also works against Candida species and various non-dermatophyte molds that can sometimes cause or complicate nail infections.5PubMed Central. Efinaconazole in the treatment of onychomycosis In lab testing, efinaconazole showed uniformly strong activity against Aspergillus species at very low concentrations and performed well against Fusarium species at concentrations where itraconazole, a widely used oral antifungal, had virtually no effect.6PubMed Central. An Assessment of In Vitro Antifungal Activities of Efinaconazole and Itraconazole against Common Non-Dermatophyte Fungi Causing Onychomycosis
When tested head-to-head against other antifungals in the lab, efinaconazole showed higher activity against dermatophytes than ciclopirox (the older topical nail lacquer) and itraconazole (the oral triazole), with potency comparable to terbinafine and amorolfine.7PubMed. Efinaconazole in Onychomycosis
Getting Through the Nail Barrier
Raw killing power against fungal cells does not help much if the drug gets stuck in the nail plate and never reaches the infection underneath. This is where Jublia’s formulation gives it a meaningful edge. Efinaconazole has an unusually low affinity for keratin, the protein that makes up the nail. In practical terms, it does not bind tightly to the nail material and instead passes through it relatively freely to accumulate in the nail bed where the fungus lives.
Researchers measured this by suspending keratin in a solution with efinaconazole and two competing topical drugs, ciclopirox and amorolfine. About 14% of the efinaconazole remained free and unbound in the keratin suspension, compared to less than 1% for ciclopirox and about 2% for amorolfine. Efinaconazole also released more easily from keratin after binding, with roughly half of the bound drug washing off, a much higher proportion than for either competing treatment.8PubMed Central. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment
This low keratin affinity has a direct clinical consequence. Because ciclopirox binds heavily to nail keratin, much of its antifungal activity is spent on the nail plate itself rather than the nail bed. Efinaconazole, by contrast, passes through the plate and mainly exerts its effect in the nail bed, where the fungal infection is concentrated.9PubMed Central. Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum Think of it as the difference between a sponge (ciclopirox, which soaks into the nail and stays there) and water flowing through a mesh (efinaconazole, which moves through and out the other side).
How Jublia Stacks Up Against Other Topical Options
Toenail fungus patients in the United States have had three main topical prescription options in recent years: Jublia (efinaconazole), Kerydin (tavaborole), and the older Penlac (ciclopirox nail lacquer). Each works through a different mechanism, and the differences in performance are significant.
In a laboratory comparison using Trichophyton rubrum, the dermatophyte most commonly behind toenail infections, efinaconazole required far lower concentrations to inhibit growth than tavaborole or ciclopirox. Beyond just stopping growth, efinaconazole was the only one of the three that achieved complete fungal eradication in a time-dependent manner. Tavaborole slowed the fungus temporarily but the organism regrew afterward, and ciclopirox showed no activity at the concentrations tested.10PubMed Central. Fungicidal Activity in the Presence of Keratin as an Important Factor Contributing to In Vivo Efficacy: A Comparison of Efinaconazole, Tavaborole, and Ciclopirox
That same study also tested the three drugs in an animal nail infection model. All three significantly reduced fungal counts compared to untreated controls, but efinaconazole produced significantly lower viable fungal counts than either tavaborole or ciclopirox. The gap was meaningful, not marginal.
One thing to keep in mind is that lab potency does not always translate perfectly to real-world results. Adherence, nail thickness, severity of infection, and individual physiology all play a role. But the lab data helps explain why Jublia’s clinical trial results tend to be the strongest among the topical options.
What the Clinical Trial Results Look Like
Clinical trials give a more grounded picture of what you can realistically expect from Jublia. The pivotal phase III trials used a 48-week, once-daily treatment period. After this course, the mycological cure rate (meaning the lab test came back negative for fungus) was promising, but the complete cure rate, which requires both a negative lab test and the nail looking nearly normal, was more modest. This gap frustrated both patients and researchers.
A longer-term study followed patients who continued applying efinaconazole beyond the initial 48 weeks. At the final assessment, the treatment success rate (defined as less than 10% of the nail still visually affected) reached about 57%, the complete cure rate was about 31%, and the mycological cure rate was roughly 62%. All of these numbers increased over the course of treatment, suggesting that sticking with the medication longer improved outcomes.11PubMed Central. Efficacy of long‐term treatment with efinaconazole 10% solution in patients with onychomycosis, including severe cases: A multicenter, single‐arm study
For context, a complete cure rate around 30% may sound discouraging, but it is one of the highest among topical treatments for toenail fungus. Oral antifungals like terbinafine generally outperform topicals, which is why they remain the first-line choice for moderate to severe infections. Still, for people who cannot take oral medications or prefer to avoid them, Jublia offers the strongest topical option currently available.
Why Treatment Takes So Long
One of the most common frustrations with Jublia is the timeline. You apply it daily for 48 weeks, nearly a full year, and even then the nail may still look abnormal. This is not necessarily because the drug has failed.
Toenails grow slowly, roughly a millimeter per month for the big toe. Once the fungus is killed in the nail bed, the damaged portion of the nail still has to grow out completely before the nail looks healthy again. The big toenail takes anywhere from 12 to 18 months to fully replace itself. So even if efinaconazole successfully eliminates the fungal infection at the cellular level, you may still see discolored or thickened nail for months afterward simply because the old, damaged nail has not been replaced yet.
Researchers have identified this slow outgrowth as a major reason for the gap between mycological cure and complete cure. A trial examining extended use of efinaconazole for up to 24 months found that both mycological cure and clinical effectiveness continued to improve beyond the standard 12-month treatment window, without any increase in side effects. The authors concluded that failure to achieve visual cure was more likely due to insufficient nail outgrowth than to any failure of the drug to work.12PubMed Central. Extended Use of Topical Efinaconazole Remains Safe and Can Provide Continuing Benefits for Dermatophyte Toenail Onychomycosis
This finding has practical implications. If you have been using Jublia for a year and the lab test shows the fungus is gone but the nail still looks bad, continuing treatment while waiting for the nail to grow out may be worthwhile. Stopping too early could allow residual fungus, hidden in microscopic pockets, to re-establish itself before the healthy nail fully replaces the damaged one.
Practical Tips That Improve Results
How you prepare your nails before applying Jublia can make a real difference in how well the drug works. Dermatology guidelines recommend trimming and thinning the affected nail as much as possible before starting topical treatment. Clipping away loose or lifted portions of nail and filing down thickened areas reduces the barrier the drug has to cross.13PubMed Central. Nail Society of India Recommendations for Pharmacologic Therapy of Onychomycosis
For very thick, deformed nails, applying 40% urea cream under a bandage can soften and partially dissolve the nail plate, making it easier for a topical antifungal to penetrate afterward. This is not a substitute for the antifungal itself but rather a way to improve its delivery. Physical thinning or chemical softening are adjunctive measures, meaning they help the main treatment work better but cannot cure the infection on their own.
Beyond nail prep, consistency matters. Jublia is designed for once-daily application directly to the affected toenail and the surrounding skin. The solution is applied using a built-in brush tip, which deposits a thin film that dries without requiring a bandage. Unlike ciclopirox nail lacquer, which requires periodic filing and removal of old layers, Jublia does not build up on the nail surface and does not require debridement between applications. Patients in clinical studies reported higher satisfaction and quality of life with efinaconazole compared to older topical regimens, likely because the daily routine was simpler.
Does the Fungus Develop Resistance to Jublia
Drug resistance is a reasonable concern with any antimicrobial you use for months at a time. Researchers tested this directly by exposing Trichophyton rubrum strains to efinaconazole repeatedly in the lab (12 passages) and in an animal model over eight weeks. No evidence of resistance development emerged under those conditions.14PubMed Central. In vitro and in vivo assessment of dermatophyte acquired resistance to efinaconazole, a novel triazole antifungal
This is encouraging, though the real world introduces variables that a controlled lab setting does not fully capture. Incomplete treatment courses, missed doses, and sub-therapeutic drug levels at the infection site could theoretically promote resistant strains over time. No published reports of clinically significant efinaconazole resistance have emerged as of this writing, but the drug has only been available since 2014, which is relatively short in the lifespan of an antifungal.
Recurrence After Successful Treatment
Even when toenail fungus is genuinely cured, it frequently comes back. Recurrence may affect more than half of successfully treated patients within a year or more of completing treatment.15PubMed Central. Onychomycosis: Practical Approaches to Minimize Relapse and Recurrence This is not a failure of the drug but a reflection of the conditions that led to the infection in the first place. The same warm, moist environment inside shoes that encouraged the original infection remains, and re-exposure to dermatophytes in communal areas like gym showers or pool decks is common.
Distinguishing relapse from reinfection matters. Relapse means the original infection was never fully eradicated and reappears from residual fungus. Reinfection means a new fungal exposure causes a fresh infection after the old one was cured. In practice, the distinction is hard to make without sophisticated genetic testing, but either way the result is the same: the nail starts thickening and discoloring again.
Strategies that may help reduce recurrence include maintaining good foot hygiene, wearing breathable footwear, treating athlete’s foot promptly (since the same dermatophytes cause both conditions), and some dermatologists recommend periodic prophylactic application of a topical antifungal to the nails even after a cure is achieved.
When Oral Medications Are Not an Option
Jublia occupies a particularly important niche for patients who cannot safely take oral antifungals. Terbinafine and itraconazole, the two most effective oral options, are processed by the liver, and both carry drug interaction risks that complicate treatment in people taking multiple medications. For people with diabetes, who are disproportionately affected by toenail fungus, the overlap between onychomycosis treatment and their existing medication regimens creates real challenges. Oral antifungals can be complicated by comorbidities and the polypharmacy common in diabetic patients, which heightens the risk of contraindications and harmful interactions between drugs.16Journal of Dermatological Treatment. Treating onychomycosis in diabetic patients: risk, therapy, and topical opportunity
Because Jublia is applied topically, virtually none of the drug enters the bloodstream. This eliminates the liver toxicity concerns and drug interactions associated with oral therapy. For elderly patients, diabetic patients, and anyone on complex medication regimens, this makes Jublia a treatment that can be used safely where oral options cannot. The extended-use trial that followed patients for up to 24 months specifically confirmed that Jublia remained safe even for elderly participants over the longer treatment period.12PubMed Central. Extended Use of Topical Efinaconazole Remains Safe and Can Provide Continuing Benefits for Dermatophyte Toenail Onychomycosis
The tradeoff is effectiveness. For moderate to severe infections, oral antifungals still produce higher cure rates. But for mild to moderate cases, or for patients where the oral route is too risky, Jublia provides a treatment pathway that did not meaningfully exist before 2014. The combination of strong antifungal potency, low keratin binding, and negligible systemic absorption makes it a genuinely different kind of topical than what came before.